#Liver2013 imaging of hepatic lesions, highlight of the PG course for me so far
December 3, 2024 at 3:18 PM
#Liver2013 imaging of hepatic lesions, highlight of the PG course for me so far
#Liver2013 Day 2 of PG course: Dr. Tran gives nice, concise overview of common clinical scenarios in HBV that lack consensus guidelines
December 3, 2024 at 3:18 PM
#Liver2013 Day 2 of PG course: Dr. Tran gives nice, concise overview of common clinical scenarios in HBV that lack consensus guidelines
#Liver2013 HCV rx talks at PG course (drs. Reau and Jacobson) The present is already past and the future is bright but in a state of flux
December 3, 2024 at 3:18 PM
#Liver2013 HCV rx talks at PG course (drs. Reau and Jacobson) The present is already past and the future is bright but in a state of flux
#Liver2013 Dr. Vargas reports that interferon-free options for HCV patients who have received a liver transplant may be available soon
December 3, 2024 at 3:18 PM
#Liver2013 Dr. Vargas reports that interferon-free options for HCV patients who have received a liver transplant may be available soon
#Liver2013 PG course: Dr. Morgan, prednisone and pentoxifylline effective for severe alcoholic hepatitis but combo doesn't increase benefit
December 3, 2024 at 3:18 PM
#Liver2013 PG course: Dr. Morgan, prednisone and pentoxifylline effective for severe alcoholic hepatitis but combo doesn't increase benefit
#Liver2013 PG course: Dr. Hay, disparity in liver transplant rates between women and men has increased since implementation of MELD in US
December 3, 2024 at 3:18 PM
#Liver2013 PG course: Dr. Hay, disparity in liver transplant rates between women and men has increased since implementation of MELD in US
#Liver2013 PG course: Dr. Garcia-Tsao proposes an algorithm for the diagnosis and treatment of Acute Kidney Injury in cirrhosis
December 3, 2024 at 3:18 PM
#Liver2013 PG course: Dr. Garcia-Tsao proposes an algorithm for the diagnosis and treatment of Acute Kidney Injury in cirrhosis
#Liver2013 highlights of 11/2 poster session include HCV pipeline and economics of care
December 3, 2024 at 3:18 PM
#Liver2013 highlights of 11/2 poster session include HCV pipeline and economics of care
#Liver2013 common themes from transplant plenary are enhanced access of HCC patients to transplant, pros, cons and consequences
December 3, 2024 at 3:18 PM
#Liver2013 common themes from transplant plenary are enhanced access of HCC patients to transplant, pros, cons and consequences
#Liver2013 it's not even 10 am yet and the New HCV therapeutics area is packed with viewers http://t.co/azYyLSPqkx
December 3, 2024 at 3:13 PM
#Liver2013 it's not even 10 am yet and the New HCV therapeutics area is packed with viewers http://t.co/azYyLSPqkx
#Liver2013 poster 1084: compassionate use, sofosbuvir data offer hope to patients with aggressive recurrent HCV post-liver transplantation
December 3, 2024 at 3:13 PM
#Liver2013 poster 1084: compassionate use, sofosbuvir data offer hope to patients with aggressive recurrent HCV post-liver transplantation
#Liver2013 poster 1092 12 wks of Simeprevir/P/R +12 wks of PR cures 70% G1a relapsers but cure rate only 47% if Q80K mutation present (12%)
December 3, 2024 at 3:13 PM
#Liver2013 poster 1092 12 wks of Simeprevir/P/R +12 wks of PR cures 70% G1a relapsers but cure rate only 47% if Q80K mutation present (12%)
#Liver2013 NS5a/5b ledipasvir/sofosbuvir + ribavirin or non nuc NS5b GS-9669 for 12 weeks, safe, effective in G1 advanced fibrosis/cirrhosis
December 3, 2024 at 3:13 PM
#Liver2013 NS5a/5b ledipasvir/sofosbuvir + ribavirin or non nuc NS5b GS-9669 for 12 weeks, safe, effective in G1 advanced fibrosis/cirrhosis
#Liver2013 MK-5172+MK-8742, the NS3/4a+NS5a, once a day combo, well tolerated and cures around 90% G1 non cirrhotics in C-WORTHY study
December 3, 2024 at 3:13 PM
#Liver2013 MK-5172+MK-8742, the NS3/4a+NS5a, once a day combo, well tolerated and cures around 90% G1 non cirrhotics in C-WORTHY study
#Liver2013 In phase 2, NS5a/NS3/NS5b combo of daclatasvir/asunaprevir/BMS-791325 twice a day for 12 weeks, cures 92% mostly G1a patients
December 3, 2024 at 3:13 PM
#Liver2013 In phase 2, NS5a/NS3/NS5b combo of daclatasvir/asunaprevir/BMS-791325 twice a day for 12 weeks, cures 92% mostly G1a patients
#Liver2013 All-oral Sofosbuvir+ribavirin well tolerated and achieves 77% SVR4 in patients with recurrent HCV post-liver transplant
December 3, 2024 at 3:13 PM
#Liver2013 All-oral Sofosbuvir+ribavirin well tolerated and achieves 77% SVR4 in patients with recurrent HCV post-liver transplant
#Liver2013 oral combo of (soon to be) approved sofosbuvir/simeprevir +/- ribavirin gives >96% SVR4 in G1 naives /nulls with F3-4 fibrosis
December 3, 2024 at 3:13 PM
#Liver2013 oral combo of (soon to be) approved sofosbuvir/simeprevir +/- ribavirin gives >96% SVR4 in G1 naives /nulls with F3-4 fibrosis
#Liver2013 COSMOS implications when drugs available are obvious. Third party payers, patients, advocates, treaters and others with dilemma
December 3, 2024 at 3:13 PM
#Liver2013 COSMOS implications when drugs available are obvious. Third party payers, patients, advocates, treaters and others with dilemma
#Liver2013 HCV recurrence after transplant in "not so sick" pts with sofosbuvir/RBV prevented in many. >30 d HCV pcr neg=more likely to work
December 3, 2024 at 3:13 PM
#Liver2013 HCV recurrence after transplant in "not so sick" pts with sofosbuvir/RBV prevented in many. >30 d HCV pcr neg=more likely to work
#Liver2013 LONESTAR-2 improves on FUSION SVR12 to 83% in G3 experienced patients +/- cirrhosis by adding P/R to sofosbuvir for 12 weeks
December 3, 2024 at 3:08 PM
#Liver2013 LONESTAR-2 improves on FUSION SVR12 to 83% in G3 experienced patients +/- cirrhosis by adding P/R to sofosbuvir for 12 weeks
#Liver2013 high rate of 12% HCV positivity among ER "baby boomers" in urban AL. Impact of new therapies requires large scale screening!
December 3, 2024 at 3:08 PM
#Liver2013 high rate of 12% HCV positivity among ER "baby boomers" in urban AL. Impact of new therapies requires large scale screening!
#Liver2013 poster 1445 supports emerging theme of liver disease improving when HCV is treated in patients with HCC and non HCC cancers
December 3, 2024 at 3:08 PM
#Liver2013 poster 1445 supports emerging theme of liver disease improving when HCV is treated in patients with HCC and non HCC cancers
#liver2013 Dr. Janssen (HCV symposium) Benefits of SVR go beyond liver improvement to reduction in HCC risk and renal /cardiovascular risk
December 3, 2024 at 3:08 PM
#liver2013 Dr. Janssen (HCV symposium) Benefits of SVR go beyond liver improvement to reduction in HCC risk and renal /cardiovascular risk
#Liver2013 HCV symposium: use of simeprevir/sofosbuvir combo debated during Q&A session. Debate will likely go on in clinics across US...
December 3, 2024 at 3:08 PM
#Liver2013 HCV symposium: use of simeprevir/sofosbuvir combo debated during Q&A session. Debate will likely go on in clinics across US...
#Liver2013 oral NS3/NS5a combo of asunaprevir/daclatasvir well tolerated, cures 85% non responders or IFN-ineligible G1b Japanese patients
December 3, 2024 at 3:08 PM
#Liver2013 oral NS3/NS5a combo of asunaprevir/daclatasvir well tolerated, cures 85% non responders or IFN-ineligible G1b Japanese patients